Universe · entity

Caligan Partners LP

Institutional manager (13F) · CIK 1727492
13F holdings · as of 2026-03-31 · top 24 · reported portfolio $1.4B
#IssuerValueShares
1LIQUIDIA CORPORATION$306M8,118,892
2ABIVAX SA$163M1,461,924
3REVOLUTION MEDICINES INC$161M1,652,808
4VAXCYTE INC$120M2,060,719
5XENON PHARMACEUTICALS INC$81M1,393,027
6MINERALYS THERAPEUTICS INC$75M2,772,654
7EXELIXIS INC$67M1,553,262
8TANGO THERAPEUTICS INC$50M2,408,798
9TYRA BIOSCIENCES INC$49M1,276,968
10SPYRE THERAPEUTICS INC$44M878,127
11ADMA BIOLOGICS INC$43M4,756,511
12LB PHARMACEUTICALS INC$35M1,438,070
13VOR BIOPHARMA INC$34M1,925,066
14SAB BIOTHERAPEUTICS INC$31M7,967,207
15OPUS GENETICS INC$28M6,075,028
16INVENTIVA SA$28M4,974,906
17MBX BIOSCIENCES INC$25M848,590
18AVALO THERAPEUTICS INC$24M1,635,023
19ANIKA THERAPEUTICS INC$21M1,435,130
20MAZE THERAPEUTICS INC$18M614,962
21VERRICA PHARMACEUTICALS INC$5M923,910
22SENSEI BIOTHERAPEUTICS INC$4M126,002
23AURA BIOSCIENCES INC$2M229,864
24XILIO THERAPEUTICS INC$943k112,128
All filings on EDGAR ↗

Source: sec_edgar_13f · public regulatory · retrieved 2026-06-29. Public SEC data; no contact information.